The pipeline is primarily attacking the problem from three unique biological angles:
1. The Myostatin / Activin Blockers (The Heavy Hitters)
Myostatin is the body’s natural brake pedal for muscle growth—it prevents your muscles from getting too big. By blocking myostatin or its related pathways (activin), these injectable antibodies essentially take the brakes off muscle creation, forcing the body to hold onto or build lean tissue even while starving.
- Bimagrumab: Acquired by E.Why.Willie for nearly $2 billion, this antibody blocks activin receptors. While Lilly strategically halted a trial for Type 2 diabetes patients, a major Phase 2b trial (the BELIEVE study) evaluating it in non-diabetic GLP-1 users showed that combining it with semaglutide heavily accelerated fat loss while significantly sparing muscle mass.
- Apitegromab: Developed by Scholar Rock, this drug selectively inhibits myostatin activation. In highly anticipated Phase 2 clinical data published in Nature Medicine, researchers demonstrated that adding apitegromab to Lilly's tirzepatide (Mounjaro/Zepbound) preserved 55% more muscle mass compared to taking the weight-loss drug alone.
- Trevogrumab & Garetosmab: Regeneron Pharmaceuticals is testing a powerful combination cocktail alongside semaglutide. Their clinical trials found that using trevogrumab offered a 51.3% boost in muscle preservation, but adding their secondary antibody (garetosmab) into the mix further boosted muscle preservation to an incredible 80.9%.
2. The Muscle Machine Activators (Urocortin 2)
Instead of just blocking a muscle restriction pathway, this approach flips on a biological switch that explicitly tells the body to burn fat and rebuild tissue at the cellular level.
HM17321: This novel drug is a urocortin 2 analog that activates fat metabolism while physically stimulating muscle tissue growth. In August 2026, Swiss pharma giant Roche placed a massive bet on this mechanism, paying $190 million upfront (and up to $2.3 billion total) to license the asset from South Korea’s Hanmi Pharm as a premium GLP-1 companion shot.
3. The Daily Oral Pills
For people who are tired of injecting themselves multiple times a week, a sub-class of alternative muscle-retaining options are transitioning into Phase 2 testing as simple daily tablets.
- Enobosarm: Developed by Veru, this is a daily oral selective androgen receptor modulator (SARM). A 2026 clinical meta-analysis presented to the American Diabetes Association showed that enobosarm explicitly forced the body to target fat mass while increasing total lean muscle by up to 4%. A dedicated Phase 2b trial is underway testing it directly alongside GLP-1 medications in older adults.
- Pill 001 (Atrogi): Biotech firm Atrogi successfully completed a small-scale trial on a first-of-its-kind oral tablet that functions as a selective beta-2 modulator. Early data shows it successfully achieves fat loss alongside an actual increase in functional muscle strength, paving the way for full Phase 2 trials.
Click to expand...
nypost.com
